According to the Zhitong Finance App, Xianjian Technology (01302) released its 2021 results. The company achieved revenue of 925 million yuan, an increase of 44.1% over the previous year; profit attributable to shareholders was 292 million yuan, an increase of 35% over the previous year; and a profit of 6.8 points per share.
According to the announcement, the increase in earnings was mainly due to laminated stents, CERA blockers and LambreTMRevenue from sales of left ventricular occlusion devices increased. The increase in net profit was mainly due to an increase in gross profit and a decrease in expenses.